Sterigenics International Acquires Toxikon’s European Laboratory Business

Sterigenics International LLC has announced that it has acquired Toxikon Europe N.V., the European division of Toxikon Corporation, a Bedford, Mass.-based preclinical contract research organization. Terms of the deal were not disclosed.
 
Toxikon Europe N.V. provides a suite of integrated analytical, material characterization and microbiological services to the pharmaceutical, medical device and biologics industries. The company’s unrivaled extractables and leachables (E&L) testing expertise and leading database enhance the flexibility and speed with which its life science customers can bring their products to market.
 
This acquisition provides a more comprehensive service offering and a platform for growth for Sterigenics International’s Nelson Labs business. Nelson Labs will now offer Toxikon Europe’s leading E&L capabilities to its customers around the world and in kind, offer Nelson Labs leading microbiological services to Toxikon Europe’s customers.
 
“Toxikon Europe’s geographic foothold and expert analytical testing platform enable our global expansion and ability to provide significantly greater value to customers,” said Michael B. Petras Jr., CEO of Sterigenics International. “We are excited to welcome a strong management team, with over 150 years of aggregate industry experience, and the highly trained Toxikon Europe employees to our company.”
 
Toxikon Europe’s capabilities are both complementary and additive to Nelson Labs’ existing testing portfolio and, in combination, make Nelson Labs one of the premiere global E&L laboratory testing platforms for the pharmaceutical and medical device industries.
 
As part of this deal, Nelson Labs and Toxikon USA will enter into a long-term supply arrangement under which Nelson Labs will outsource in-vivo biocompatibility to Toxikon USA.
 
“The acquisition of Toxikon Europe and our ongoing partnership with Toxikon USA support our strategy to offer greater breadth of services to meet the demands of our rapidly growing, global customer base,” said Jeff Nelson, president of Nelson Labs. “We are now able to serve the pharmaceutical and medical device industries continuously from the early stages of product development through manufacturing, sterilization, and testing.”
 
“For Toxikon Europe, the acquisition by Sterigenics International validates our success and provides our customers with additional resources,” said Dr. Laxman Desai, president and CEO, Toxikon Corporation. “Our team at Toxikon USA looks forward to our continued partnership with Nelson Labs.”
 
Jos Bollen, managing director, Toxikon Europe, added, “Our customers, who are increasingly focused on quality and safety, will continue to receive the superior service and quality they have come to know from Toxikon Europe. In addition, our breadth of service and our reach will be enhanced with the expertise and industry leadership of Sterigenics International’s Nelson Labs.”